Severe asthma is related to high societal costs and decreased health related quality of life

Abstract Purpose Previous studies found higher levels of pain severity and disability to be associated with higher costs and lower health-related quality of life. However, these findings were based on cross-sectional data and little is known about the longitudinal relationships between pain severity and disability versus health-related quality of life and costs among chronic low back pain patients. This study aims to cover this knowledge gap by exploring these longitudinal relationships in a consecutive cohort. Methods Data of 6316 chronic low back pain patients were used. Measurements took place at 3, 6, 9, and 12 months. Pain severity (Numeric pain rating scale; range: 0–100), disability (Oswestry disability index; range: 0–100), health-related quality of life (EQ-5D-3L: range: 0–1), societal and healthcare costs (cost questionnaire) were measured. Using linear generalized estimating equation analyses, longitudinal relationships were explored between: (1) pain severity and health-related quality of life, (2) disability and health-related quality of life, (3) pain severity and societal costs, (4) disability and societal costs, (5) pain severity and healthcare costs, and (6) disability and healthcare costs. Results Higher pain and disability levels were statistically significantly related with poorer health-related quality of life (pain intensity: − 0.0041; 95% CI − 0.0043 to − 0.0039; disability: − 0.0096; 95% CI − 0.0099 to − 0.0093), higher societal costs (pain intensity: 7; 95% CI 5 to 8; disability: 23; 95% CI 20 to 27) and higher healthcare costs (pain intensity: 3; 95% CI 2 to 4; disability: 9; 95% CI 7 to 11). Conclusion Pain and disability were longitudinally related to health-related quality of life, societal costs, and healthcare costs. Disability had a stronger association with all outcomes compared to pain.

Download Full-text

Herbal MedicineCordyceps sinensisImproves Health-Related Quality of Life in Moderate-to-Severe Asthma

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2016/6134593 ◽

2016 ◽

Vol 2016 ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

Ningqun Wang ◽

Jie Li ◽

Xiaobo Huang ◽

Wenqiang Chen ◽

Yujing Chen

Keyword(s):

Quality Of Life ◽

Treatment Group ◽

Lung Function ◽

Severe Asthma ◽

Cordyceps Sinensis ◽

Control Group ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Moderate-to-severe asthma has a substantial impact on the health-related quality of life (HR-QOL) of the patients.Cordyceps sinensisis a traditional Chinese medicine that is evaluated clinically for the treatment of many diseases, such as chronic allograft nephropathy, diabetic kidney disease, and lung fibrosis. In order to investigate the effects ofCordyceps sinensison patients with moderate-to-severe persistent asthma, 120 subjects were randomized to receive Corbin capsule containingCordyceps sinensisfor 3 months (treatment group,n=60), whereas the control group (n=60) did not receive treatment with Corbin capsule. Inhaled corticosteroid and as-neededβ-agonists were used in the treatment of both groups. HR-QOL was measured with the Juniper’s Asthma Quality of Life Questionnaire (AQLQ). The incidence of asthma exacerbation, pulmonary function testing, and serum measurements of inflammatory mediators were also evaluated. The results showed that the treatment group indicated a significant increase in AQLQ scores and lung function compared with the control group. The expression levels of the inflammation markers IgE, ICAM-1, IL-4, and MMP-9 in the serum were decreased and IgG increased in the treatment group compared with the control group. Therefore, the conclusion was reached that a formulation ofCordyceps sinensisimproved the HR-QOL, asthma symptoms, lung function, and inflammatory profile of the patients with moderate-to-severe asthma. This trial is registered withChiCTR-IPC-16008730.

Download Full-text

PBI1 Liberty Asthma Traverse Dupilumab Shows Sustained Efficacy and Improvements in Asthma Control and Health-Related Quality of Life (HRQOL) in Patients with Moderate-to-Severe Asthma

Value in Health ◽

10.1016/j.jval.2021.04.072 ◽

2021 ◽

Vol 24 ◽

pp. S14

Author(s):

M. Wechsler ◽

L.B. Ford ◽

J.F. Maspero ◽

I.D. Pavord ◽

D. Langton ◽

...

Keyword(s):

Quality Of Life ◽

Asthma Control ◽

Severe Asthma ◽

Health Related Quality ◽

Sustained Efficacy ◽

Related Quality ◽

Health Related

Download Full-text

Dupilumab Consistently Improves Rhinoconjunctivitis-Specific Health-Related Quality of Life in Patients With Uncontrolled, Moderate-to-Severe Asthma and Comorbid Allergic Rhinitis: Results from the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.307 ◽

2019 ◽

Vol 143 (2) ◽

pp. AB101 ◽

Cited By ~ 1

Author(s):

Jean Bousquet ◽

Jorge F. Maspero ◽

Bradley E. Chipps ◽

Jonathan Corren ◽

J. Mark FitzGerald ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Severe Asthma ◽

Health Related Quality ◽

Phase 3 ◽

Related Quality ◽

Health Related ◽

Specific Health

Download Full-text

Targeting treatable traits in severe asthma: a randomised controlled trial

European Respiratory Journal ◽

10.1183/13993003.01509-2019 ◽

2019 ◽

Vol 55 (3) ◽

pp. 1901509 ◽

Cited By ~ 11

Author(s):

Vanessa M. McDonald ◽

Vanessa L. Clark ◽

Laura Cordova-Rivera ◽

Peter A.B. Wark ◽

Katherine J. Baines ◽

...

Keyword(s):

Quality Of Life ◽

Randomised Controlled Trial ◽

Asthma Control ◽

Severe Asthma ◽

Controlled Trial ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Randomised Controlled

RationaleTreatable traits have been proposed as a new paradigm for airway disease management.ObjectivesTo characterise treatable traits in a severe asthma population and to determine the efficacy of targeting treatments to these treatable traits in severe asthma.MethodsParticipants (n=140) with severe asthma were recruited to a cross-sectional study and underwent a multidimensional assessment to characterise treatable traits. Eligible participants with severe asthma (n=55) participated in a 16-week parallel-group randomised controlled trial to determine the feasibility and efficacy of management targeted to predefined treatable traits, compared to usual care in a severe asthma clinic. The patient-reported outcome of health-related quality of life was the trial's primary end-point.Main resultsParticipants with severe asthma had a mean±sd of 10.44±3.03 traits per person, comprising 3.01±1.54 pulmonary and 4.85±1.86 extrapulmonary traits and 2.58±1.31 behavioural/risk factors. Individualised treatment that targeted the traits was feasible and led to significantly improved health-related quality of life (0.86 units, p<0.001) and asthma control (0.73, p=0.01).ConclusionsMultidimensional assessment enables detection of treatable traits and identifies a significant trait burden in severe asthma. Targeting these treatable traits using a personalised-medicine approach in severe asthma leads to improvements in health-related quality of life, asthma control and reduced primary care acute visits. Treatable traits may be an effective way to address the complexity of severe asthma.

Download Full-text